Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Keyphrases
Adjuvant Therapy
21%
Advanced Melanoma
8%
Cancer Patients
10%
Cancer Therapy
10%
Cancer Treatment
20%
Chemotherapy
9%
Clinical Trials
9%
Cutaneous Melanoma
14%
Distant Metastasis
6%
Distant Metastasis Free Survival
6%
Doxorubicin
7%
EORTC
18%
European Organizations
17%
Hazard Ratio
10%
High Dose
8%
High Risk
11%
In Cancer
13%
In-transit Metastasis
7%
Interferon alpha-2b
6%
Interferon-α (IFN-α)
22%
Interleukin-2
15%
Ipilimumab
11%
Isolated Limb Perfusion
46%
Isolated Perfusion
8%
Malignant Melanoma
9%
Melanoma
81%
Melanoma Patients
26%
Melphalan
37%
Metastatic Melanoma
14%
Natural Killer Cells
7%
Overall Survival
15%
Pembrolizumab
16%
Perfusion
13%
Phase II Trial
10%
Placebo
15%
Primary Melanoma
9%
Prognostic Factors
12%
Prognostic Value
7%
Randomized Phase III Trial
8%
Recurrence-free Survival
9%
Response Rate
7%
Sarcoma
6%
Sentinel Lymph Node
16%
Sentinel Lymph Node Biopsy
12%
Soft Tissue Sarcoma
9%
Stage III Melanoma
21%
Tumor
31%
Tumor Cells
9%
Tumor Necrosis Factor-α
46%
Tumor Response
8%
Medicine and Dentistry
Adjuvant Therapy
16%
Biopsy Technique
7%
Breast Cancer
6%
Cancer Treatment
11%
Chemotherapy
5%
Clinical Trial
7%
Diseases
14%
Fine-Needle Aspiration
5%
Hazard Ratio
6%
Immunotherapy
12%
In-Transit Metastasis
5%
Interferon
8%
Interleukin 2
5%
Ipilimumab
8%
Isolation Perfusion
5%
Limb
13%
Limb Perfusion
29%
Liver Metastasis
6%
Lymph Node
5%
Malignant Neoplasm
18%
Melanoma
100%
Melanoma Skin Cancer
11%
Melphalan
25%
Metastatic Carcinoma
10%
Metastatic Melanoma
9%
Neoplasm
21%
Oncology
7%
Overall Survival
13%
Pembrolizumab
11%
Phase III Trials
5%
Placebo
10%
Prognostic Factor
10%
Radiation Therapy
5%
Rectum Cancer
5%
Recurrence Free Survival
10%
Recurrent Disease
12%
Retroperitoneal Lymph Node Dissection
11%
Sentinel Node
19%
Soft Tissue Sarcoma
11%
Survival Rate
5%
Tumor
21%
Tumor Necrosis
5%
Tumor Necrosis Factor
21%
